

PATENT SPECIFICATION

(11) 1 475 503

1 475 503

(21) Application No. 58986/73 (22) Filed 19 Dec. 1973

(23) Complete Specification filed 9 Dec. 1974

(44) Complete Specification published 1 June 1977

(51) INT CL² A61K 31/335

(52) Index at acceptance

A5B 381 38Y 39X 420 421 422 423 426 42Y 442 44Y 480
482 483 48Y 493 49Y 501 503 50Y 510 51Y 540
54Y 550 55Y 565 566 56Y 576 57Y 586 58Y 616
61Y 644 64Y 654 65Y 664 66Y

(72) Inventor THOMAS JAMES SULLIVAN




(54) TOPICAL COMPOSITIONS

(71) We, FISONS LIMITED, a British Company, of Fison House, 9 Grosvenor Street, London W.1., do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

The present invention relates to topical compositions and a new method for treating diseases of the skin.

Compounds of the general formula



and therapeutically acceptable salts, esters and amides thereof, [wherein R¹, R², R³, R⁴, R⁵ and R⁶ are the same or different and each is H or halogen, C 1 to 6 alkyl, hydroxy, C 1 to 6 alkoxy, C 2 to 6 alkenyl benzyloxy, nitro, C 1 to 6 alkyl or C 1 to 6 alkoxy substituted by hydroxy, C 1 to 6 alkoxy, carboxy or by halogen, and X is a saturated or unsaturated, straight or branched polymethylene chain which may be unsubstituted or substituted by one or more hydroxy, C 1 to 6 alkoxy or hydroxy-substituted C 1 to 6 alkoxy groups, and which may be interrupted by one or more carbocyclic rings or oxygen-containing heterocyclic rings, oxygen atoms or carbonyl groups,] have been proposed for use in the treatment of the allergic disorders, notably allergic asthma, by administration by inhalation of a powder formulation or of a nebulised aqueous formulation.

Surprisingly, we have now found that these compounds have pharmacological activity when administered externally to the skin of a mammal and are thus indicated for use in the treatment of chronic skin disorders in mammals, e.g. man.

Accordingly, the present invention provides a method for the treatment of chronic skin disorders which comprises the external appli-

cation of an effective amount of a compound of general formula I or a pharmaceutically acceptable salt, ester or amide thereof to the skin of a mammal, other than a human, suffering from a chronic skin disorder.

We prefer to use those compounds of formula I in which R¹, R², R³, R⁴, R⁵ and R⁶ are the same or different and each is a hydrogen or halogen atom (e.g. a chlorine, bromine, iodine or fluorine atom), a C 1 to 6 alkyl (e.g. a methyl, ethyl, propyl, isopropyl, butyl or tertiary butyl group), hydroxy, C 1 to 6 alkoxy (e.g. a methoxy, ethoxy, propoxy, isopropoxy, butoxy or tertiary butoxy group) or substituted C 1 to 6 alkyl or C 1 to 6 alkoxy group, (for example a hydroxyloweralkoxy, loweralkoxyloweralkoxy, carboxyloweralkoxy, hydroxyloweralkyl or haloloweralkyl such as chloro-, bromo-, iodo- or fluoro-loweralkyl), a C 2 to 6 alkenyl, e.g. allyl or methyl-allyl, benzyl or nitro, and X is a saturated or unsaturated, substituted or unsubstituted, straight or branched polymethylene chain which may be interrupted by one or more carbocyclic rings or oxygen containing heterocyclic rings, (e.g. benzene, dioxan, tetrahydrofuran, or dihydropyran rings), oxygen atoms or carbonyl groups.


The term "lower" as used herein denotes up to 6 carbon atoms.

In general, it is preferred that no more than one of R¹, R² and R³ and no more than one of R⁴, R⁵ and R⁶ is other than hydrogen and are selected from a hydrogen or halogen atom or an alkyl, hydroxy, alkoxy or substituted alkoxy group, and X has the meaning defined above.

Particularly preferred compounds of formula I are those in which all of R¹, R², R³, R⁴, R⁵ and R⁶ are hydrogen.


The group X may be any of a wide variety of groups. Thus, for example, it may be a straight or branched saturated or unsaturated hydrocarbon chain. Further, X may be such a chain interrupted by one or more oxygen atoms, carbonyl groups or carbocyclic or heterocyclic rings and may be substituted by one or more halogen atoms (e.g. chlorine, bromine, iodine or fluorine atoms), or hydroxy

or C 1 to 6 alkoxy (e.g. methoxy, ethoxy, propoxy, isopropoxy, butoxy, tert-butoxy, etc) groups. Specific examples of the group X are groups of the formulae:




etc.

The group X is preferably a straight or branched hydrocarbon chain, which may be interrupted by one or more oxygen atoms, and contains from 3 to 7 carbon atoms. Desirably such a chain is a polymethylene chain substituted by one or more hydroxyl groups, a particularly preferred chain being the 2 - hydroxy - trimethylene chain



The chain $-O-X-O-$ may link different or corresponding positions on the chromone molecules.

Thus, the preferred compounds of formula I for present use are those of the general formula:



Suitable pharmaceutically acceptable salts include, for example, ammonium salts, alkali-metal salts (e.g. sodium, potassium and lithium), alkaline-earth metal salts (e.g. magnesium and calcium), and salts with organic amines (e.g. mono-, di- or tri-alkyl C_{1-6} amines, piperidine, and trialkanol C_{1-6} amine

salts). Esters which may be mentioned include simple alkyl esters (e.g. methyl, ethyl, propyl, isopropyl, butyl and tertiary butyl esters). Amides which may be mentioned include simple amides (for example amides with ammonia and lower alkylamines such as methylamine, ethylamine, etc.) and more complex amides with amino acids, e.g. glycine.

Specific compounds of formula I and derivatives thereof for present use are:

- Disodium salt of 1,3 - bis(2 - carboxy-chromon - 5 - yloxy)propane. 50
- Disodium salt of 1,3 - bis(2 - carboxy-chromon - 5 - yloxy) - 2 - hydroxypropane 55
- 1,3 - Bis(2 - carboxychromon - 5 - yloxy) - 2 - hydroxypropane.
- Calcium salt of 1,3 - bis(2 - carboxy-chromon - 5 - yloxy) - 2 - hydroxypropane. 60
- Magnesium salt of 1,3 - bis(2 - carboxy-chromon - 5 - yloxy) - 2 - hydroxypropane.
- Dipiperidine salt of 1,3 - bis(2 - carboxy-chromon - 5 - yloxy) - 2 - hydroxypropane. 65
- 1,12 - Bis(2 - carboxychromon - 5 - yloxy) - 2,11 - dihydroxy - 4,9 - dioxadodecane.
- 1,4 - Bis(2 - carboxychromon - 5 - yloxy)-butane. 70
- 1,5 - Bis(2 - carboxychromon - 5 - yloxy)-pentane.
- 1,6 - Bis(2 - carboxychromon - 5 - yloxy)-hexane.
- 1,10 - Bis(2 - carboxychromon - 5 - yloxy)-decane. 75
- 1,7 - Bis(2 - carboxychromon - 5 - yloxy)-2,6 - dihydroxy - 4 - oxaheptane.
- 1,5 - Bis(2 - carboxychromon - 5 - yloxy) - 3 - oxapentane. 80
- 1,4 - Bis(2 - carboxychromon - 5 - yloxy) - 2,3 - dihydroxybutane.
- 1,4 - Bis(2 - carboxychromon - 5 - yloxy) - 2 - hydroxybutane.
- 1,5 - Bis(2 - carboxychromon - 7 - yloxy)-pentane. 85
- 1,10 - Bis(2 - carboxychromon - 5 - yloxy) - 3,8 - dioxo - 4,7 - dioxodecane.
- 1,5 - Bis(2 - carboxy - 8 - chlorochromon - 5 - yloxy)pentane. 90
- 1 - (2 - Carboxychromon - 5 - yloxy) - 3 - (2 - carboxychromon - 7 - yloxy) - 2 - hydroxypropane.
- 1 - (2 - Carboxychromon - 5 - yloxy) - 5 - (2 - carboxychromon - 7 - yloxy)pentane. 95
- 1,3 - Bis(2 - carboxy - 7 - methylchromon - 5 - yloxy) - 2 - hydroxypropane.
- 1,3 - Bis(2 - carboxy - 8 - ethylchromon - 5 - yloxy) - 2 - hydroxypropane.
- 1 - (2 - Carboxychromon - 5 - yloxy) - 3 - (2 - carboxy - 8 - ethylchromon - 5 - yloxy) - 2 - hydroxypropane. 100

	1,5 - Bis(2 - carboxychromon - 8 - methylchromon - 7 - yloxy)pentane.	1,3 - Bis(8 - allyl - 2 - carboxychromon - 7 - yloxy) - propan - 2 - ol.	65
	1,3 - Bis(2 - carboxy - 8 - methylchromon - 7 - yloxy) - 2 - hydroxypropane.	1 - (8 - Allyl - 2 - carboxychromon - 7 - yloxy) - 3 - (2 - carboxychromon - 7 - yloxy) - propan - 2 - ol.	
5	1,5 - Bis(2 - carboxychromon - 5 - yloxy) - 3 - methylpentane.	1,3 - Bis(2 - carboxy - 8 - methallylchromon - 7 - yloxy) - propan - 2 - ol.	70
	1,3 - Bis(2 - carboxy - 6 - chlorochromon - 7 - yloxy) - 2 - hydroxypropane; disodium salt.	1,3 - Bis(8 - allyl - 6 - bromo - 2 - carboxychromon - 7 - yloxy)propan - 2 - ol.	
10	1 - (2 - Carboxychromon - 5 - yloxy) - 3 - (2 - carboxy - 6 - chlorochromon - 7 - yloxy) - 2 - hydroxypropane; disodium salt.	1 - (8 - Allyl - 2 - carboxychromon - 7 - yloxy) - 3 - (2 - carboxychromon - 6 - yloxy) - propan - 2 - ol.	75
	1,5 - Bis(2 - carboxychromon - 6 - yloxy)pentane.	1,5 - Bis(8 - allyl - 2 - carboxychromon - 7 - yloxy) - pentane.	
15	1,3 - Bis(2 - carboxychromone - 7 - yloxy) - 2 - hydroxypropane.	1,3 - Bis(2 - carboxy - 8 - nitrochromon - 5 - yloxy) - propan - 2 - ol.	80
	1,2 - Bis(2 - carboxychromon - 5 - yloxy-methyl)benzene.		
20	1,3 - Bis(2 - carboxychromon - 6 - yloxy) - 2 - hydroxypropane.		
	Disodium salt of 1 - (2 - carboxychromon - 5 - yloxy) - 3 - (2 - Carboxychromon - 6 - yloxy) - 2 - hydroxypropane.		85
25	Disodium salt of 1 - (2 - carboxychromon - 5 - yloxy) - 3 - (2 - Carboxychromon - 8 - yloxy) - 2 - hydroxypropane.		
	1,8 - Bis(2 - carboxychromon - 5 - yloxy)octane.		90
30	1,9 - Bis(2 - carboxychromon - 5 - yloxy)nonane.		
	1,2 - Bis(2 - carboxychromon - 5 - yloxy)ethane.		95
35	1,3 - Bis(2 - carboxychromon - 5 - yloxy) - 2 - chloromethyl - 2 - hydroxymethylpropane; dipotassium salt tetrahydrate.		
	Disodium salt of 1,3 - bis(2 - carboxychromon - 5 - yloxy) - 2 - ethoxypropane.		100
40	Disodium salt of 1,3 - bis(2 - carboxychromon - 5 - yloxy) - 2 - oxopropane.		
	Diethyl ester of 2,5 - bis(2 - carboxychromon - 5 - yloxymethyl) - dioxan.		105
	1,3 - Bis(2 - carboxy - 7 - methoxychromon - 5 - yloxy) - propan - 2 - ol.		
45	1,5 - Bis(2 - carboxy - 7 - methoxychromon - 5 - yloxy) - pentane.		
	1,3 - Bis(2 - carboxy - 5(2 - hydroxypropoxy)chromon - 7 - yloxy)propan - 2 - ol.		110
50	1,3 - Bis(2 - carboxy - 7 - (2 - hydroxypropoxy)chromon - 5 - yloxy)propan - 2 - ol.		
	1,5 - Bis(2 - carboxy - 5 - methoxychromon - 7 - yloxy)pentane.		115
55	1,5 - Bis(2 - carboxy - 7 - (2 - hydroxypropoxy) - chromon - 6 - yloxy)pentane.		
	1,3 - Bis(5 - benzyloxy - 2 - carboxychromon - 7 - yloxy) - propan - 2 - ol.		120
	1,3 - Bis(2 - carboxy - 5 - methoxy - chromon - 7 - yloxy) - propan - 2 - ol.		
60	1,3 - Bis(2 - carboxy - 5 - hydroxychromon - 7 - yloxy) - propan - 2 - ol.		
	1,3 - Bis(8 - allyl - 2 - carboxychromon - 5 - yloxy) - propan - 2 - ol.		

The compound of formula I or a pharmaceutically acceptable salt, ester or amide thereof may be applied to the skin of the mammal, notably man, in any suitable formulation. Thus, the compound of formula I may be formulated as an ointment, in which the finely ground compound of formula I is dispersed in a soft paraffin. Liquid paraffin, hard paraffin, and wool fat may be included in the ointment base. If a water miscible ointment base is desired, a polyethylene glycol may be included.

The compound of formula I may also be formulated as a cream, which may be either an oil in water type, or a water in oil type. Suitable emulsifying agents for the former type include sodium, potassium, ammonium and triethanolamine soaps; polysorbates; and cationic, anionic, and non-ionic emulsifying waxes. Suitable emulsifying agents for the latter type include calcium soaps, wool fat, wool alcohols, beeswax, and certain sorbitan esters. A preservative is usually desirable in a cream, particularly in an aqueous cream. Examples of suitable preservatives alone, or in combination, are chlorocresol, p - hydroxybenzoates, thiomersal, and chlorbutol.

The compound of formula I may also be formulated as a lotion or liniment by dissolving or dispersing the compound in an aqueous or oily base. A suitable preservative may be included in the formulation. Ethanol and/or glycerin may be included in the aqueous base. Examples of suitable oil bases include arachis oil, castor oil, and other vegetable oils. Where pastes or gels are desired, a thickening agent may be incorporated in an aqueous base. These ingredients may also serve as stabilizing agents for emulsions. Suitable agents include Carbopol (Registered Trade Mark), bentonite, soluble cellulose derivatives (e.g. sodium carboxy methyl cellulose, hydroxypropyl methyl cellulose), Veegum and polyvinyl alcohol.

Other ingredients e.g. humectants, antioxidants, perfumes and pigments may also be present if desired.

A semi-solid base that has been found particularly suitable is based on a fatty alcohol/

glycol mixture. Suitable fatty alcohols include saturated alkanols containing 16 to 24 carbon atoms and suitable glycols include 1,2 - propylene glycol, 1,3 - propylene glycol, polyethylene glycols of molecular weight 100 to 800, and dipropylene glycol. The fatty alcohol and glycol are present in from 15 to 45:45 to 85 parts by weight, preferably 20 to 35:55 to 80 parts, respectively. If desired a plasticizer, e.g. a polyethylene glycol of molecular weight 800 to 20,000 or 1,2,6 - hexanetriol, and/or a penetrant may also be present.

Typical formulations of the compound of formula I are illustrated by the following Examples:—

15	1. Ointment	
	Compound of formula I	10% w/v
	Liquid paraffin BP	10% w/v
	Wool Fat BP	10% w/v
20	White Soft Paraffin BP	70% w/v
	2. Water Miscible Ointment	
	Compound of formula I	10% w/v
	Polyethylene glycol 400	40% w/v
25	Polyethylene glycol 4000	50% w/v
	3. Aqueous Cream	
	Compound of formula I	10% w/v
	Emulsifying Ointment BP	30% w/v
30	Chlorocresol	1% w/v
	Purified Water	59% w/v
	4. Oily Cream	
	Compound of formula I	10% w/v
35	Wool alcohols BP	3% w/v
	Hard paraffin BP	12% w/v
	White Soft Paraffin BP	10% w/v
	Liquid Paraffin BP	30% w/v
40	Purified Water	35% w/v
	5. Lotion (Aqueous)	
	Compound of formula I	10% w/v
	Glycerol	20% w/v
45	Alcohol (95%)	20% w/v
	Sodium Carboxymethyl Cellulose	1% w/v
	Purified Water	49% w/v
50	6. Lotion (Oily)	
	Compound of formula I	10% w/v
	Arachis Oil	90% w/v
	7. Fatty alcohol/glycol base	
55	Compound of formula I	10% w/v
	Stearyl alcohol	27% w/v
	Propylene Glycol	63% w/v

The compound of formula I is typically present in the above formulations in from 5 to 20% by weight, notably 10 to 15%. Where solid particles of the compound are present, e.g. in a suspension or dispersion or in a powder formulation, it is preferred that these

have a predominant size of less than 10 micrometres.

The compositions for present use may be made using any appropriate technique, e.g. by dry mixing the solid ingredients or by grinding the solid ingredients together, or by emulsifying an aqueous solution of the compound of formula I with an appropriate oil base.

The compound of formula I or the derivative thereof is preferably administered to the patient merely by smearing a cream or paste over the affected area of the skin. Alternatively, the compound may be impregnated into a gauze or similar pad and this pad then applied to the affected area.

The rate of application of the compound of formula I will depend upon the severity and the surface area of the disorder to be treated and repeated applications may be made at intervals during the day, e.g. from 1 to 6 times a day.

The compounds of formula I or the pharmaceutically acceptable derivatives thereof find use in the treatment of chronic dermatoses in mammals, notably man. Dermatoses which may be treated include those involving skin mast cells and/or anti-body/antigen reactions and include eczemas, drug eruptions, psoriasis, dermatitis herpetiformis, pemphigus and chronic skin ulcers, notably those affecting man in tropical climates. The compounds of Formula I or derivatives thereof are of particular use in the treatment of atopic eczema in man.

Example 8

Ointment formulations were prepared by mixing the disodium salt of 1,3 - bis(2 - carboxychromon - 5 - yloxy) - 2 - hydroxypropane with a vaseline (Registered Trade Mark) base to give ointments containing 5 or 10% by weight of the disodium salt. These ointments were applied to patients suffering from eczemas, notably atopic eczema, by smearing the ointments on to the affected areas of the skin from 2 to 4 times a day.

In 16 patients treated an improvement in pruritus was noted after 7 to 10 days and over the test period of 4 months the ointments continued to improve the skin. In some cases the improvement was at least as good as that which would have been expected with a steroid ointment.


From another aspect, therefore, the invention also provides a composition for topical application to the skin of a mammal notably man, which comprises a compound of formula I or a pharmaceutically acceptable salt, ester or amide, notably a compound of formula II or the disodium salt thereof; in admixture with a diluent suitable for topical application to the skin.

Some of the compounds of formula I and

their preparation are described in British Patent No. 1,144,905.

WHAT WE CLAIM IS:—

1. A composition for topical application to the skin of a mammal comprising a compound of the general formula



and pharmaceutically acceptable salts, esters and amides thereof, [wherein R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are the same or different and each is H or halogen, C 1 to 6 alkyl, hydroxy, C 1 to 6 alkoxy, C 2 to 6 alkenyl benzyloxy, nitro, C 1 to 6 alkyl or C 1 to 6 alkoxy substituted by hydroxy, C 1 to 6 alkoxy, carboxy or by halogen, and X is a saturated or unsaturated, straight or branched polymethylene chain which may be unsubstituted or substituted by one or more hydroxy, C 1 to 6 alkoxy or hydroxy-substituted C 1 to 6 alkoxy groups, and which may be interrupted by one or more carbocyclic rings or oxygen-containing heterocyclic rings, oxygen atoms or carbonyl groups,] in admixture with a diluent suitable for topical application to the skin, the composition being in the form of a cream, lotion, liniment, paste or gel.


2. A composition as claimed in claim 1 wherein the diluent is selected from fatty alcohol/glycol mixtures, oil in water emulsions, a paraffin or a vegetable oil.

3. A composition as claimed in either of the preceding claims wherein the compound of formula I or the salt, ester or amide thereof is present in from 5 to 20% by weight of the composition.

4. A composition as claimed in claim 3 wherein the compound of formula I or the

salt, ester or amide thereof is present in from 10 to 15% by weight of the composition.

5. A composition as claimed in any of the preceding claims wherein the compound of formula I has the general formula:



and is present in the form of a free acid or an alkali-metal, alkaline-earth metal, ammonium or amine salt thereof or in the form of an amide or alkyl ester thereof.

6. A composition according to claim 1 substantially as hereinbefore described.

7. A composition substantially as hereinbefore described in any one of Examples 1 to 8.

8. A method for treating chronic skin disorders which comprises the external application of a compound of formula I as defined in claim 1, or a pharmaceutically acceptable salt, ester or amide thereof to the skin of a mammal, other than a human, suffering from a chronic skin disorder.

9. A method as claimed in claim 8 wherein the skin disorder is an eczema.

10. A method as claimed in claim 8 or claim 9 wherein the compound of formula I or the salt, ester or amide thereof is applied in the form of a composition as claimed in any of claims 1 to 7.

11. A method for the treatment of chronic skin disorders as claimed in any of claims 8 to 10, and substantially as hereinbefore described.

F. MURPHY,
Agent for the Applicants,
Fisons Limited,
Fison House,
Princes Street,
Ipswich,
Suffolk IP1 1QH.

12/12/12

1
